Bayesian Capital Management’s Apogee Therapeutics APGE Stock Holding History

Bayesian Capital Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$571K	Buy	+4,300	New	+$387K	0.37%	75
2024 Q4	–	Sell	-11,878	Closed	-$698K	–	677
2024 Q3	$698K	Buy	+11,878	New	+$569K	0.08%	307
2024 Q2	–	Sell	-6,771	Closed	-$450K	–	716
2024 Q1	$450K	Buy	+6,771	New	+$296K	0.04%	458
2023 Q4	–	Sell	-11,142	Closed	-$237K	–	733
2023 Q3	$237K	Buy	+11,142	New	+$245K	0.03%	521

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Bayesian Capital Management's APGE Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 4,300 shares worth $571K. The stake represents 0.37% of the portfolio and ranks #75 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in APGE as recently as Q3 2024.

Bayesian Capital Management first reported a position in APGE in Q3 2023 and has held it in 4 quarters since. The position peaked at $698K in Q3 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Bayesian Capital Management held 4,300 shares of Apogee Therapeutics worth $571K as of Q2 2026.
Apogee Therapeutics was a new Bayesian Capital Management position in Q2 2026.
Apogee Therapeutics made up 0.37% of Bayesian Capital Management's portfolio in Q2 2026, its #75 holding.
Bayesian Capital Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 4 quarters since.
Bayesian Capital Management's Apogee Therapeutics position peaked at $698K in Q3 2024.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.